Xcout Intel
Numab Therapeutics
Numab Therapeutics is a Swiss biotechnology company developing multispecific antibody-based medicines that modulate immune-cell interactions. Its programs target serious diseases including cancer and immune-mediated or inflammatory disorders, serving patients through development and potential partnerships with pharmaceutical companies.
Subscribe to see Numab Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Numab Therapeutics at a glance
Numab Therapeutics is a biotech company. Xcout tracks 13 named people at Numab Therapeutics, including Barbara Angehrn (Chief Executive Officer).
Numab Therapeutics leadership
- Barbara AngehrnChief Executive Officer
- Stefan WarmuthChief Technology Officer
- Carlo IncertiChairman of the Board
- David UrechDirector, Chair R&D Committee
- Oliver MiddendorpDirector
- Alain BertalloVP People & Culture / IT / Facility Management
7 more named people on record for Numab Therapeutics, with roles, board committees and tenure — see the full roster →
Get Numab Therapeutics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Numab Therapeutics in Xcout Intel
- 13 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access